Idelalisib: A novel PI3Kδ inhibitor for chronic lymphocytic leukemia

Annals of Pharmacotherapy

Volumn 49, Issue 10, 2015, Pages 1162-1170

  Shah, Arpita ^a   Mangaonkar, Abhishek ^a  

^a Georgia Regents Medical Center   (United States)

Author keywords

CAL 101; GS 101; Idelalisib; PI3K ; Relapsed chronic lymphocytic leukemia

Indexed keywords

AGANIRSEN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; IDELALISIB; RITUXIMAB; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COMORBIDITY; CONCENTRATION AT STEADY-STATE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INFUSION RELATED REACTION; INTESTINE PERFORATION; LEUKEMIA RELAPSE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURINES; QUINAZOLINONES; RECURRENCE; RITUXIMAB; TREATMENT OUTCOME;

EID: 84952774594     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015594813     Document Type: Review

References (38)

1. American Cancer Society. Cancer Facts and Figures 2015. Atlanta, GA: American Cancer Society; 2015.
2. National Comprehensive Cancer Network. Non-Hodgkin's lymphoma. Version 2. 2015. NCCN Clinical Practice Guidelines in Oncology. http://www. nccn. org. Accessed March 1, 2015.
3. Danilov A. Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther. 2013;35: 1258-1270.
4. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
5. Cuneo A, Cavazzini F, Ciccone M, et al. Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer Med. 2014;3: 555-564.
6. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121: 1403-1412.
7. Foa R, Guarini A. A mechanism-driven treatment for chronic lymphocytic leukemia? N Engl J Med. 2013;369:85-87.
8. Chung C, Lee R. Ibrutinib, obinutuzuamb, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia. Pharmacotherapy. 2014;34:1298-1316.
9. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975-980.
10. Byrd J, Jones J, Woyach J, et al. Entering era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol. 2014;32:3039-3047.
11. Jones JA, Byrd J. How will B-cell-receptor-targeted therapies change future of CLL therapy? Blood. 2014;123:1455-1460.
12. Khan M, Saif A, Sandler S, et al. Idelalisib for the treatment of chronic lymphocytic leukemia. ISRN Oncol. 2014;931858. doi:10. 1155/2014/931858.
13. Idelalisib (Zydelig) [production information]. Foster City, CA: Gilead Sciences, Inc; 2014. http://www. accessdata. fda. gov/drugsatfda_ docs/label/2014/205858lbl. pdf. Accessed March 1, 2015.
14. Fiorcari S, Brown WS, McIntyre BW, et al. The PI3-kinase delta inhibitor Idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cells to endothelial and marrow stromal cells. PLoS One. 2013;8(12):e83830. doi:10. 1371/journal. pone. 0083830.
15. Young RM, Staudt LM. Targeting pathological B cell receptor signaling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12:229-243.
16. Hacken E, Burger J. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia-focus on the B-cell receptor. Clin Cancer Res. 2014;20:548-556.
17. Markham A. Idelalisib: first global approval. Drugs. 2014;74:1701-1707.
18. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Best Pract Res Clin Hematol. 2010;23:133-143.
19. Yang Q, Modi P, Newcomb T, Queva C, Gandhi V. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21:1537-1542.
20. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078-2088.
21. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110δ inhibitor, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390-3397.
22. Barrientos JC, Coutre SE, de Vos S, et al. Long-term followup of a phase 1 trial of idelalisib in combination with bendamustine, bendamustine/rituximab, fludarabine, chlorambucil, or chlorambucil/rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Paper presented at: 56th Annual Meeting of the American Society of Hematology; December 6-9 2014; San Francisco, CA.
23. Furman RR, De Vos S, Barrientos JC, et al. Long-term follow-up of a phase 1 study of idelalisib in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia. In: Paper presented at: 56th Annual Meeting of the American Society of Hematology; December 6-9, 2014; San Francisco, CA.
24. De Vos S, Furman RR, Barrientos JC, et al. Idelalisib, a selective inhibitor of PI3Kdelta, in combination with bendamustine, fludrabine or chlorambucil in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Paper presented at: 55th Annual Meeting of the American Society of Hematology; December 7-10, 2013; New Orleans, LA.
25. Furman R, Sharman J, Coutre S, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-1007.
26. Sharman JP, Coutre SE, Furman JP, et al. Second interim analysis of a phase 3 study of idelalisib (ZydligR) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract no. 330]. Paper presented at: 56th Annual Meeting of the American Society of Hematology; December 6-9, 2014; San Francisco, CA.
27. Zelenetz A, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia or small lymphocytic lymphoma. Paper presented at: 56th Annual Meeting of the American Society of Hematology; December 6-9, 2014; San Francisco, CA.
28. O'Brien SM, Lamanna N, Kipps TJ, et al. Update on a phase 2 study of idelalisib in combination with rituximab in treatment- naive patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Paper presented at: 56th Annual Meeting of the American Society of Hematology; December 6-9, 2014; San Francisco, CA.
29. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Eng J Med. 2014;370:1101-1110.
30. Coutre SE, Leonard JP, Barrimentos JC, et al. Clinical activity of idelalisib (GS-1101), a selective inhibitor of PI3Kdelta, in phase 1 and 2 trials in chronic lymphocytic leukemia (CLL): effect of del(17p)/TP53 mutation, del(11q), IGHV mutation, and NOTCH1 mutation. Paper presented at: 55th Annual Meeting of the American Society of Hematology; December 7-10, 2013; New Orleans, LA.
31. Keating G. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma. Target Oncol. 2015;10:141-151.
32. Coutre S, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment-expert panel opinion. Leuk Lymphoma. 2015;1:1-20.
33. European Medicines Agency. Summary of opinion (initial authorization) Zydelig (idelalisib) [media release]. 24 July 2014. http://www. ema. europa. eu/docs/en_GB/document_ library/Summary_of_opinion_-_Initial_authorisation/ human/003843/WC500170181. pdf. Accessed March 1, 2015.
34. Brown JR, Hillmen P, O'Brien S, et al. Updated efficacy including genetic and clinical subgroup analysis and overall efficacy in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. 2014;124:Abstract 3331.
35. O'Brien S, Jones JA, Coutre S, et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE-17 trial. Blood. 2014;124;Abstract 327.
36. Redbook [online database]. http://www. redbook. com/redbook/ online. Accessed March 1, 2015.
37. Awan FT, Byrd JC. New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res. 2014;20:5869-5874.
38. Desai AV, El-Bakkar H, Abdul-Hay M. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future. Clin Lymphoma Myeloma Leuk. 2015;15:314-322. doi:10. 1016/j. clml. 2014. 09. 007.